HomeSeaStar Medical

SeaStar Medical

Selective Cytopheretic Device Study in Pediatric Patients with Acute Kidney Injury Shows Positive Results

Selective Cytopheretic Device study's primary objective was to assess the safety of the device in children. Safety was determined by adverse events related to treatment up to 60 days following treatment initiation.

Aethlon Medical, Inc. and SeaStar Medical, Inc. Announce Strategic Joint Cross-Licensing Agreement

"The potential synergy of our two companies' platforms should allow penetration into multiple unaddressed markets," said Timothy C. Rodell, M.D., Interim Chief Executive Officer of Aethlon Medical.